The burgeoning field of innate immune-mediated disease and autoinflammation. by Peckham, D et al.
This is an author produced version of The burgeoning field of innate immune-mediated 
disease and autoinflammation..
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/107921/
Article:
Peckham, D orcid.org/0000-0001-7723-1868, Scambler, T, Savic, S 
orcid.org/0000-0001-7910-0554 et al. (1 more author) (2017) The burgeoning field of 
innate immune-mediated disease and autoinflammation. Journal of Pathology, 241 (2). pp. 
123-139. ISSN 0022-3417 
https://doi.org/10.1002/path.4812
© 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons,
Ltd. This is the peer reviewed version of the following article: Peckham, D., Scambler, T., 
Savic, S. and McDermott, M. F. (2016), The burgeoning field of innate immune-mediated 
disease and autoinflammation. J. Pathol., which has been published in final form at 
https://doi.org/10.1002/path.4812. This article may be used for non-commercial purposes 
in accordance with Wiley Terms and Conditions for Self-Archiving.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
For Peer Review






	

	




	
	



	 	



 

	 
	  
!"	 #$%&'"%"!!(%
)'*
%+&'"%"

$
,"

-
%&'"%!.
."
$

,"

-

%
&'"%"

$
,"

-
+	 
#.	 
+/	 



http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
For Peer Review
 1
	

	




	
	

 (short title



	
	

Daniel Peckham1, Thomas Scambler2, Sinisa Savic2,3, Michael F. McDermott2  
 
1 Leeds Centre for Cystic Fibrosis, St James's University Hospital, Leeds, UK. 
2 National Institute for Health Research–Leeds Musculoskeletal Biomedical Research 
Unit (NIHR.LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine 
(LIRMM), Wellcome Trust Brenner Building, St James’s University  Hospital, Beckett 
Street, Leeds, UK  
3Department of Clinical Immunology and Allergy, St James’s University Hospital, 
Leeds UK 
 
Correspondance: Daniel Peckham D.G.Peckham@leeds.ac.uk and Michael 
McDermott M.McDermott@leeds.ac.uk 
Keywords:  autoinflammatory, pyrin, NLRP3, inflammasome, cystic fibrosis, IFN, 
proteasome 



   Immune.mediated autoinflammatory diseases are occupying an increasingly 
prominent position among the pantheon of debilitating conditions that afflict mankind. 
This review focuses on some of the key developments which have occurred since 
the original description of autoinflammatory disease, in 1999, and focuses on 
underlying mechanisms that trigger autoinflammation. The monogenic 
Page 1 of 44
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 2
autoinflammatory disease range has expanded considerably during that time, and 
now includes a broad spectrum of disorders, including relatively common conditions 
such as cystic fibrosis and subsets of systemic lupus erythematosus. The innate 
immune system also plays a key role in the pathogenesis of complex inflammatory 
disorders. We have proposed a new nomenclature to accommodate the rapidly 
increasing number of monogenic disorders, which predispose to either 
autoinflammation or autoimmunity or, indeed, combinations of both. This new 
terminology also encompasses a wide spectrum of genetically determined 
autoinflammatory diseases, with variable clinical manifestations of immunodeficiency 
and immune dysregulation/autoimmunity. We also explore some of the ramifications 
of the breakthrough discovery of the physiologic role of pyrin and the search 
for identifiable factors that may serve to trigger attacks of autoinflammation. The 
evidence that pyrin, as part of the pyrin inflammasome, acts as a sensor of different 
inactivating bacterial modification Rho GTPases, rather than directly interacting with 
these microbial products, sets the stage for a better understanding of the role of 
micro.organisms and infections in the autoinflammatory disorders. Finally, we 
discuss some of the triggers of autoinflammation as well as potential therapeutic 
interventions aimed at enhancing autophagy and proteasome degradation pathways. 
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   “La fixité du milieu intérieur est la condition de la vie libre et indépendante”  
Claude Bernard in “Leçons sur les phénomènes de la vie communs aux animaux et 
aux végétaux”. Paris, Paris, Baillière, 1878.1879, 2 vols; 404 p. and 564 
“The constancy of the internal environment is the condition for a free and 
independent life” in (Lessons on the physiological properties and pathological 
changes of body fluids) 
 
     Since the discovery of mutations in the pyrin protein as the cause of familial 
Mediterranean fever (FMF), in 1997 [1,2], a veritable treasure trove of susceptibility 
genes, with associated signalling pathways and potential disease mechanisms have 
been unearthed, which, in turn, has provided some essential guidelines on the most 
effective therapies for these debilitating conditions [3,4]. The term “autoinflammation” 
was first proposed by Dan Kastner, in 1999, [5] to differentiate between the 
pathogenesis of various hereditary periodic fever syndromes (HPFs), which are 
uncommon causes of recurrent fevers in clinical practice, and that of autoimmune 
diseases, characterized by the presence of autoantibodies and autoantigen.specific 
T and B cells. In particular, autoinflammation describes the type of inflammation 
mediated by the innate immune system [6], and the expression of pyrin in key cells 
of this system, including neutrophils, monocytes, dendritic cells, and serosal 
fibroblasts reflects this. Mutations in other central regulators of the innate immune 
system, as described below, have subsequently been found to underlie a range of 
other monogenic conditions as well as polygenic autoinflammatory diseases [7], 
such as Behcet’s and Crohn’s disease [8,9] (Figs. 1). 
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   With relatively recent advances in massively parallel sequencing and wider use of 
this technology, we have witnessed the discovery of a succession of monogenic 
disorders, predisposing to either autoinflammation or autoimmunity or, indeed, 
combinations of both, further revealing the complex functioning of the human 
immune system [3,9,10]. These novel monogenic diseases may be of limited clinical 
impact, in the overall scheme of things, but they do represent true experiments of 
nature that continue to provide unique pathogenic insights into the hierarchy and 
levels of regulation of organ.specific immune defence responses. To quote directly 
from DJ Weatherall “if the severity of their phenotypes can be reduced by genetic or 
even environmental factors, it may be possible to reproduce these effects 
pharmacologically” [11]. 
    Furthermore, functional studies of these disorders have generated many new and 
surprising biological concepts; for example, the discovery that autosomal recessive 
mutations of the mevalonate kinase gene (MVK), a key step in the cholesterol 
pathway, caused hyperimmunoglobulinemia D with periodic fever syndrome (HIDS) 
[12,13], has prompted closer examination of the broader interactions between 
inflammation and overall lipid signalling. The expanding list of novel 
autoinflammatory diseases and associated susceptibility genes has already been 
extensively covered [3,14]; in this review we propose to describe a selection of these 
diseases in order to illustrate some of the many unanticipated developments in this 
field, which have arisen as a result of the study of genetic causes of 
autoinflammation, often in quite rare conditions.
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       In 2002, the late Jurg Tschopp’s laboratory reported reported on the 
identification of an intracellular complex called the NOD.like receptor family, pyrin 
domain containing 3 (NLRP3) inflammasome that triggered activation of 
inflammatory caspases, with pro.interleukin 1β (pro.IL.1β) processing and 
subsequent secretion of pro.inflammatory IL.1β [15] (Fig. 2). The genetic basis of 
familial cold autoinflammatory syndrome (FCAS) [16], Muckle.Wells syndrome 
(MWS) [17,18] and chronic infantile neurologic, cutaneous, articular syndrome/ 
neonatal.onset multisystem inflammatory disease (CINCA/NOMID) [19,20], were all 
found to be associated with mutations in the NLRP3/CIAS1 gene, and evidence that 
release of IL.1β was central to the pathogenesis of MWS came with the 
demonstrated efficacy of interleukin.1 receptor antagonist (IL.1Ra), anakinra, in 2 
patients with MWS [21]. Collectively, the spectrum of these conditions soon became 
known as cryopyrin associated periodic syndrome (CAPS), reflecting a shared 
aetiopathogenesis (Table 1).  Furthermore, as it quickly became apparent that this 
collection of conditions responded exquisitely to IL.1 blockade [21.23], so too it 
gradually emerged that IL.1 inhibition was also effective in other HPFs, like TNF 
receptor.associated periodic syndrome  (TRAPS) [24], HIDS and FMF [25], although 
the response was less predictable in some cases. So it was proposed that caspase.
1 activation with release of IL.1β was a pathway common to many autoinflammatory 
conditions; the mutated NLRP3 produces a gain of function, with lack of feedback 
inhibition, that results in constitutive activation of the NLRP3 inflammasome with IL.
1β and IL.18 release [3,26]. The interleukin.1 receptor antagonist (IL.1Ra) provides 
a “biological brake” on inflammation driven by either endogenous IL.1α or IL.1β; 
deficiency of IL.1Ra (DIRA) [27] and deficiency of IL.36 receptor antagonist (IL.
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36Ra) (DITRA) lead to unopposed IL.36 signalling and pustular psoriasis [28,29] 
(Table 1). 
  A broad range of autoinflammatory diseases is currently being treated with IL.
1 cytokine blockade, with marked attenuation of symptoms and disease progression. 
Canakinumab is a high affinity fully human monoclonal anti.human interleukin 1β 
antibody and rilonacept (IL.1 Trap) is a long.acting dimeric fusion protein IL.1 
blocker. Clinical trials have been undertaken in CAPS, gouty arthritis, and systemic 
juvenile idiopathic arthritis (sJIA) [30.33]. There is a growing literature supporting the 
use of these agents in a wide spectrum of autoinflammatory conditions, including 
gout, Schnitzler syndrome, and Blau syndrome [34]. While multiple studies are 
ongoing, these agents have already been approved by for the treatment of CAPS 
and sJIA by a number of drug regulatory bodies.  
       Finally, somatic mosaicism has been reported in a number of autoinflammatory 
conditions. Since the first ever report of somatic mosaicism, in a Japanese patient 
with CINCA/NOMID in 2005 [35], it has subsequently been reported in several cases 
of CAPS, as well as FMF [36] and TRAPS [37]. 
   

	
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Aicardi.Goutières syndromes (AGS) constitute a collection of rare 
inflammatory disorders, associated with aberrant sensing of DNA/RNA, and usually 
affecting the brain and skin with clinical onset, most often, in early childhood. Since 
the initial description, of mutations in genes encoding the 3′→5′ exonuclease TREX1 
in patients with AGS1 [38,39], in 2006, a total of seven AGS susceptibility genes 
have been identified to date, and this wide range of genetic mutations all lead to 
excessive interferon (IFN).producing responses, known as type I interferonopathies 
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[40]. A variety of disease mechanisms are involved: AGS 1.6 are of autosomal 
recessive inheritance and the AGS 7 patients have autosomal dominant gain.of.
function mutations in the interferon induced with helicase C domain 1 (IFIH1) gene.  
     TREX1 is induced as part of the IFN.stimulatory DNA (ISD) response, an antiviral 
pathway that detects DNA, triggering immune activation through IRF3 [41]. Both 
TREX1 and SAMHD1 (AGS5) act as a negative regulators of the ISD response [42]. 
The genotype.phenotype spectrum of TREX1 is remarkably broad and complex 
[43]. Familial chilblain lupus, systemic lupus erythematosus (SLE) and retinal 
vasculopathy with cerebral leukodystrophy have all been associated with mutations 
in TREX1 [44], in addition to the AGS1 phenotype, which, in its more severe form, is 
characterized by intracranial calcifications, cerebral atrophy, leukodystrophy, chronic 
cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha.interferon (IFNα) and 
negative serologic investigations for prenatal infections. 
Individuals with AGS7 also have severe neurologic impairment and 
immunological disease, particularly SLE [45]. However, clinical variability and non.
penetrance are notable features of some AGS7 patients, despite the presence of IFN 
up.regulation (increased expression of type I IFN regulated genes, referred at as an 
IFN signature). 
     A variety of therapies have been used to treat the chronic excessive IFN 
production in AGS patients. Anti.inflammatory therapies, including Janus kinase 
(JAK) inhibitors, such as baricitinib and tofacitinib, and IFN pathway.blocking drugs, 
such as sifalimumab, have all been been used in AGS [46,47]. If AGS progresses to 
antibody.mediated disease then anti.B cell therapy, such as rituximab may be of 
benefit. Reverse transcriptase inhibitors (RTIs) are also being used to treat severely 
affected AGS patients and results are awaited with interest.  
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     Apart from AGS there is a growing list of interferonopathies, due to gain.of.
function mutations in genes such as the PSMB8, present in most patients with 
chronic atypical neutrophilic dermatosis with lipodystrophy and elevated 
temperature/ proteasome.associated autoinflammatory syndrome 
(CANDLE/PRAAS) syndrome [48]. Liu et al. have demonstrated that mutations in the 
stimulator of interferon genes (STING) lead to constitutive STING–IFN.β pathway 
activation in patients with STING.associated vasculopathy with onset in 
infancy (SAVI) (STING is also known as transmembrane protein 173) [49]. A clinical 
trial aiming to assess the effect of JAK inhibitors, in SAVI and other related 
autoinflammatory syndromes, is currently ongoing (ClinicalTrials.gov number, 
NCT01724580). 
It has been proposed that IL.1β and type I IFN are the main drivers, 
respectively, of autoinflammation and autoimmunity, acting as counterregulators of 
each other by activating specific metabolic signalling pathways to limit either innate 
or adaptive immune responses [50]. However, the fine details of such regulatory 
networks remain to be established.    
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Autophagy is emerging as a major pathway involved in the pathogenesis of 
autoinflammatory disease. The MVK mutation, and the subsequent depletion in 
isoprenoid synthesis, reduces functional autophagy in HIDS. However, this is not the 
only autoinflammatory disease where defective autophagy contributes to disease 
pathogenesis. Autophagy is a cellular process that maintains homeostasis by the 
clearance of redundant or damaged cellular components. There is a close 
relationship between autophagy and the inflammasomes, with evidence that 
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autophagy has a role in inhibiting the inflammasomes. This evidence not only 
suggests that autophagy clears inflammasome activators, such as ROS [51,52], 
mtDNA [53], HMGB1.DNA [54] and β.amyloid plaques in Alzheimer’s disease [55], 
but also clearance of the inflammasome itself [56]. Studies inhibiting autophagy 
observe increased NLRP3 inflammasome activation due to ROS accumulation [57].  
The autophagy mechanism is a regulated process of ‘self.eating’ where the 
contents of entire organelles are recycled for other biological functions. Mutations in 
proteins such as NLRP3 or TNFR1, can overcome normal protein homeostatic 
mechanisms, resulting in autoinflammatory diseases, such as CAPS and TRAPS 
[58]. The inflammasomes are at the centre of the pathogenesis of autoinflammatory 
diseases and so the involvement of autophagy in these conditions may uncover new 
therapeutic targets. TRAPS is known to have inflammasome activation and 
individuals with TRAPS respond well to anakinra. Defective autophagy within TRAPS 
contributes to NF.κB signalling, ROS production and defective TNF.induced 
apoptosis [59,60]. Autophagy deficiency can be considered as a causal link between 
a pathological mutation and subsequent protein accumulation, inflammasome 
activation and cytokine secretion [59,60]. This is particularly relevant in inflammatory 
diseases with known protein misfolding and ER stress. One such example is cystic 
fibrosis (CF), which has been shown to have defective autophagy [61.63] and 
common infections of Burkholderia cepacia complex (B. cenocepacia), which is able 
to inhibit autophagy as part of its infection machinery [64,65]. Autophagy and the 
inflammasomes go hand.in.hand, so in order to expose new disease mechanisms of 
innate immune driven diseases, both should be considered in tandem. On the other 
hand, genetic defects in the proteasome cause protein accumulation and 
proteasome dysfunction, which can trigger IFN.dependent autoinflammation. Loss.
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of.function proteasome subunit mutations in CANDLE/PRAAS patients also promote 
type I IFN production [48,66]. 
 

	&	
&	
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
Many different factors trigger activation of NLRP3; this is a 2.stage process 
requiring priming, usually via toll.like receptor (TLR) signalling, with a 2nd signal, 
typically intracellular calcium (Ca2+) ion release, potassium (K+) flux or intracellular 
reactive oxygen species (ROS). An ever.increasing number of molecules, in the form 
of whole pathogens, toxins, pathogen.associated molecular patterns (PAMPs), and 
DAMPs, are being found to trigger activation of the different inflammasomes, in 
particular the NLRP3 inflammasome (Fig. 3). It is most unlikely that these diverse 
agents bring about the activation by direct interactions with the intracellular NLRP3 
receptor; instead, it is probable that NLRP3 is responding to generic cellular stress.
signals induced by this variety of triggers. Among the cellular mechanisms that have 
evolved to maintain protein homeostasis include proteasome.mediated degradation 
of ubiquitinated proteins and the unfolded protein response (UPR). The UPR 
prevents protein overload in the secretory pathway and also prevents the spread of 
inflammation by degrading pro.inflammatory protein complexes, such as the NLRP3 
inflammasome [58]. 
 
($%	(%
	
	$
Cystic Fibrosis (CF) is a life.threatening autosomal recessive disorder of 
the lungs and digestive system [67,68]. The defective gene CFTR results in 
abnormalities in production and function of the CFTR protein, causing dysregulation 
of epithelial fluid transport and inflammation [69.72] and a predisposition to recurrent 
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pulmonary infections due to pathogens such as Pseudomonas aeruginosa (P. 
aeruginosa) and B. cenocepacia. Alterations in function and localisation of CFTR 
within leukocytes and epithelial tissues results in an exaggerated inflammatory 
response, with production of a wide spectrum of proinflammatory and chemotactic 
cytokines such as IL.17, IL.8, IL.6, IL.1β, IL.18, TNF, upregulation of TLRs and 
lipopolysaccharide (LPS) response [73]. The neutrophil is the predominant cell type 
infiltrating the CF lung, like a primary inflammatory response seen in acute infection, 
with inflammation in CF airways being driven by local environmental cells 
(macrophages and bronchial epithelial cells), rather than T cell derived lymphokines, 
as a systemic immune response. CF exhibits many hallmarks of an autoinflammatory 
condition [10], with infiltration by innate immune cells (neutrophils and macrophages) 
at target sites, and a paucity of autoantibodies or autoreactive T cells.  
       The physiological drive to autoinflammation in CF is due to CFTR dysfunction, 
which results in abnormal airway surface liquid (ASL) dehydration, reduced airway 
luminal pH, increased ASL glucose and hyperuricaemia [74.76]. These changes 
provide a milieu for activation of the NLRP3 inflammasome [77.79]. In human 
macrophages, IL.1β secretion and caspase.1 activation occurs following extracelluar 
acidification, which is abolished following knockout of mRNA expression of NLRP3 
receptor [79].   
        As well the physiological changes in epithelial ion transport, abnormal CFTR 
production, function and trafficking results in a state of hyperinflammation, 
associated with expansion of the endoplasmic reticulum (ER), located within the 
cytoplasm of cells, that inhibits ROS.mediated autophagy [61,80,81]. The most 
common mutation F508 results in a misfolded protein which is retained intracellularly 
and results in defective autophagy due to transglutaminase (TG2).mediated 
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depletion of Beclin 1 and overactivation of protein kinase CK2 [81]. Normal 
autophagy activity suppresses activation of AIM2 and NLRP3 inflammasomes and 
helps regulate inflammation[82]. Reduced autophagy induces aberrant activation of 
the inflammasomes with accumulation of bacterial containing phagosomes [82,83]. 
In CF murine airways and human macrophages, defective CFTR results in reduce 
levels of scaffold protein, CAV1, reduced inhibition of TLR4 signalling and 
hyperinflammation [84,85]. Similarly, studies in human CF broncho.epithelial cells 
show evidence of increased NLRP3 activation and defective NLRC4 activity, which 
can be inhibited by IL.1Ra (Fig. 3) [86]. Increased levels of ceramide appear to 
trigger the inflammasome protein complex, with upregulation of ASC protein, 
caspase.1 and increased production of IL.1β and IL.18 cytokines in the lungs of a 
CF mouse model [69]. 
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         The UPR, is activated in airways of patients by recurrent bacterial infections 
[30]. The ER stress responses involve atypical UPR induction, with lack of PERK.
eIF2α response to P. aeruginosa [87]. This atypical UPR fails to resolve ER stress in 
CF and sensitises innate immunity to respond vigorously to microbial challenge. This 
persistent autoinflammatory response is associated with CF arthropathy in 9% of 
adults, which in some cases is associated with a fever and rash [88].  The complex 
relationship between inflammation, CFTR, innate immunity and infection is poorly 
understood and may be related to macrophage dysfunction, abnormal phagocytic 
killing of P aeruginosa [89] and impaired degranulation of antimicrobial proteins 
through defective activation of GTP.binding protein, Rab27a [90]. In addition, CFTR 
dysfunction results in an increase sensitivity to LPS (a major constituent of the outer 
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membrane of Gram.negative bacteria) stimulation, altered inflammatory signaling 
due to abnormal neutrophil extracellular trap formation [89,91,92] and activation of 
micro.RNAs (miRNAs) [93] and NF.κB. These bacteriae trigger the NLRP3 
inflammasome through cytosolic receptors resulting in increased caspase 1 protease 
(CASP.1) and IL1B and IL18 production (Fig. 3). Triggers of NLRP3 inflammasome 
include the common CF lung pathogens Staphylococus aureus, Haemophilus 
influenza, P. aeruginosa, B cepacia complex, rhinovirus, influenza and Aspergillus 
fumigatus [94.99].  
         Viruses activate inflammasome.mediated innate immunity through recognition 
of viral RNA [100] by TLR7 and other triggers including altered ion flux with activation 
of NLRP3 and NLRC5.  P. aeruginosa and Burkholderia cenocepacia (B. 
cenocepacia) are two major pathogens which when isolated in sputum of patients 
with CF are associated with clinical deterioration.  B. cenocepacia is particularly 
pathogenic and can result in acute clinical deterioration  with uncontrolled 
inflammation, necrotizing pneumonia and bacteraemia.  B. cenocepacia accentuates 
inflammation via upregulation of mononuclear cell IL.1β processing  and inhibition of 
autophagy [101,102]. Stimulation of autophagy with rapamycin in the CF lungs 
mouse model reduces both inflammation and infection induced by B. cepacia [102]. 
LPS, L.Ala.γ .D.Glu.m.diaminopimelic acid (m.DAP), muramyl dipeptide (MDP) 
present in gram.negative and some gram.positive bacteria are also involved 
inactivation of the innate immune systems, though TLR and Nod.like receptor (NLR) 
proteins. Furthermore, a number of chemicals can induce structural changes in LPS, 
and subsequently modify the inflammatory response [103]. CF.associated ER stress 
responses involve atypical UPR induction, with lack of PERK.eIF2α response to the 
P. aeruginosa organism [87]. This shows that the atypical UPR fails to resolve ER 
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stress in CF and sensitises innate immunity to respond vigorously to microbial 
challenge. 
A key component of the UPR is the IRE1 enzyme, activated by ER stress. 
IRE1 induces conversion of the transcription factor XBP1u mRNA (unspliced) to 
spliced XBP1 (XBP1s), the active form. Martinon et al. proposed a pro.inflammatory 
role for IRE1, with TLR2 and TLR4 activating IRE1 to induce sXBP1 [104]. In 
macrophages, IRE1 activation exacerbates secretion of proinflammatory cytokines 
such as IL.6, TNF and IFNβ [105]. Furthermore, the effects of defective XBP1 
functioning in autoinflammatory diseases may be augmented by concomitant defects 
that heighten cellular stress, including mitochondrial ROS or dysregulated microRNA 
regulation of XBP1 mediated inflammatory processes in TRAPS [106,107]. Thus, via 
both direct and indirect mechanisms, XBP1 dysregulation may be an important step 
in the cascade of intracellular events contributing to the pathogenesis of a number of 
autoinflammatory diseases. Indeed, there is also evidence of a UPR mediated by the 
XBP1s isoform in the airway epithelium of CF patients [108]. On the other hand, an 
in.vitro study from Italy shows that the degree of P. aeruginosa.dependent 
mitochondrial dysfunction is strictly dependent on defective expression of the CFTR 
channel and on a flagellin.activated TLR5.dependent pathway [109]. 
 The NLRP3 inflammasome complex also senses mitochondrial dysfunction 
[110] and intracellular ROS is a crucial element for inflammasome activation. 
Anakinra reduced endotoxin.induced airway inflammation in healthy volunteers [111], 
so we postulate that spontaneous NLRP3 inflammasome activation occurs in in CF 
patients [112]. Recent studies have linked IRE1 to NLRP3 activation [113] and have 
also shown that XBP1 modulates innate immune responses of alveolar 
macrophages in CF patients [114]. IL.1 and the NLRP3 inflammasome activation 
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cause arthropathy and the IRE1/XBP1 axis has been implicated in synovial 
macrophages and fibroblasts of RA patients [107,115]. 
            One of the unique features of CF as an autoinflammatory disease is that it is 
the only such condition to have a “laboratory proven” association with bacterial 
infections, including P. aeruginosa and B.cenocepacia. The NLRP3 and NLRC4 
inflammasomes serve different functions in regulating inflammatory responses in 
mice and humans with CF (Fig. 4). While both NLRP3 and NLRC4 inflammasomes 
contribute to pathogen clearance, NLRP3 contributes to a greater extent than 
NLRC4 to deleterious inflammatory responses in CF and correlates with defective 
NLRC4.dependent IL.1Ra production. Also IL.1 blockade markedly reduces 
inflammasome.dependent inflammation in murine and human CF  [116]. 
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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  
The relationship between inflammation and metabolism constitutes a delicate 
balance, with pathways from both systems converging to preserve the “milieu 
interieur” of the cell. This balance in maintained by short.term adaptive measures to 
keep these systems in check, but there may be a detrimental outcome when one 
arm becomes overactive and suppresses the other in the longer term. HIDS is a 
classic example of a monogenic autoinflammatory disease, with a metabolic defect 
at its core. This disease is caused by two mutations in the mevalonate kinase (MVK) 
gene [12,13,117] and presents with increased excretion of urinary mevalonic acid 
and raised immunoglobulin (Ig).D and IgA levels in the serum [118]. Symptoms are 
often neurological in nature with increased mental retardation, ataxia, seizures and 
ocular problems. Fevers usually last around 5 days and are often triggered by 
traumas, illnesses or vaccine reactions. Although not consistently successful IL.1 
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antagonists are the most effective treatment for HIDS, with steroids having limited 
efficacy [118,119]. The mutated MVK gene translates into reduced levels of the 
enzyme mevalonate kinase, which normally converts mevalonic acid into mevalonate 
.5.phosphate, an intermediate in isoprenoid and sterol synthesis. The exact 
pathogenic molecular mechanism in HIDS is not clear but recent publications, 
describing the pyrin inflammasome and its detection of bacterial modifications of Rho 
GTPases, are promising avenues of exploration, as the causal biochemical 
deficiency of isoprenoid synthesis in HIDS reduces RhoA prenylation [120]. As IL.1 
antagonists, such as anakinra and canakinumab, are able to reduce fever frequency 
and severity, the NLRP3 inflammasome is a key pathway of interest although it is not 
the only possible source of IL.1β [121]. Research advances into how the 
inflammasomes are controlled by ROS and autophagy, and their links to Rho 
GTPase prenylation, also offer significant insights into the precise metabolic and 
mitochondrial mechanisms of autoinflammatory disease. 
Recently, Celsi et al. described an increase in NLRP3 activity in a HIDS 
mouse cell model, using siRNA mvk silencing, when cells are treated with LPS and 
Iovastatin, a statin drug used to lower cholesterol [122]. However, complete 
knockdown of mvk did not induce an increase in NLRP3 activity. This lead to the 
conclusion that increased mutated mvk protein levels may trigger NLRP3 activity by 
initiating the UPR due to protein accumulation. This hypothesis is supported by a 
HIDS THP.1 macrophage cell line model [123]. This cell model produced increased 
IL.1β and IL.18 levels, as well as an altered redox state. An important role for this 
altered redox state was revealed as it was associated with increased mitochondrial 
membrane potential, increased mitochondrial damage and increased mtDNA in the 
cytosol, all linked to a defective autophagy pathway. Autophagy would ordinarily be 
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activated in the situation of an altered redox state to clear defective mitochondria and 
reduce ROS.dependent damage; however, in this cell model, autophagy was found 
to be defective. The mutations in MVK, with subsequent reduction in isoprenoid 
synthesis, causes reduced prenylation of small GTPases, which are key upstream 
proteins involved in autophagosome formation [123]. The authors suggest a model 
whereby defective autophagy, due to reduced prenylation of small GTPases, occurs 
upstream of increased mitochondrial damage and the increased ROS, in turn, 
activates the NLRP3 inflammasome [124]. Interestingly, when these small GTPases, 
specifically the Rho family, become modified they trigger the pyrin inflammasome 
[125]. The link between HIDS and reduced prenylation of Rho GTPases activating 
the pyrin inflammasome has been suggested to offer an effective therapeutic target 
[120]. RhoA activates PKN1 and PKN2 serine threonine kinases, which in turn 
phosphorylate pyrin. Phosphorylated pyrin is bound to 14.3.3 proteins that restrict 
pyrin from forming its inflammasome. Arachidonic acid is a known activator of PKN 
kinases and is a potential future therapeutic option for innate immune.mediated 
inflammation. Therefore,changes in post.translational modifications of Rho 
GTPases, in diseases such as HIDS or FMF, produce a reduced pyrin inhibitory 
capacity as well as defects in autophagy. In addition, autophagy has been shown to 
not only degrade ROS and mitochondrial debris in the cytosol, but also targets the 
NLRP3 inflammasome and pro.IL.1β for autophagosomal degradation  [126,127].  
Further evidence for disruption in metabolic pathways triggering the inflammasomes 
exists with hexokinase. Hexokinase is a glycolytic enzyme located on mitochondrial 
membranes. When inhibited, hexokinase dissociates from the membrane and allows 
release of mitochondrial DNA, activating the NLRP3 inflamamsome [128]. Metabolic 
conditions in which hexokinase function is impaired cause NLRP3 activation. 
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Bacterial peptidoglycan.derived N.acetylglucosamine is detected by mitochondrial 
membrane.bound hexokinase, causing membrane dissociation and NLRP3 
activation [129]. 
 
'"!*	&+$ 
	& 
      The interplay between various metabolic pathways and the UPR has raised the 
possibility that key points in specific metabolic pathways could be targeted in 
autoinflammatory diseases. XBP1s acts a transcriptional activator of the hexosamine 
biosynthetic (HBP) pathway [130]; the UPR.HBP axis is triggered in a variety of 
stress conditions, including ischemia.reperfusion (I/R) injury, where stimulation of 
Xbp1s induces cardio.protection by induction of HBP. Ischemic accumulation of 
succinate has been shown to control reperfusion injury through mtROS [131]. 
Therefore the prevention of succinate accumulation could be a therapeutic goal in a 
range of autoinflammatory diseases that are resistant to standard therapies. 
     The rapid advances in the pathogenesis of autoinflammatory diseases and 
recognition that altered protein homeostasis contribute an innate immune component 
to many common diseases, underlines the unmet need for novel therapies for these 
conditions. For such therapies to be effective they would need to prevent protein 
accumulation, suppress ROS generation, and enhance of clearance mechanisms 
thereby preventing the development of (auto)inflammation. Therapies that succeed 
in augmenting the UPR could prove to be highly beneficial, as protein misfolding 
within the ER leads to activation of the UPR, with associated inflammation and 
increased disease severity. Anti.oxidants could be prescribed as adjunct therapies 
for diseases with aberrant ROS production and oxidative stress, like TRAPS [131].  
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Since both autophagy and proteasome degradation have anti.inflammatory 
properties, possible therapeutic interventions will be directed towards enhancing 
these pathways to effectively reduce NLRP3 activation [132]. Small molecules that 
block the NLRP3 inflammasome and related signalling pathways have recently 
shown promise in pre.clinical studies [133.135]. Clinical trials of agents that 
modulate proteotoxic stress and deactivate the inflammasome(s), combined with 
traditional therapies, such as IL.1 antagonists, will provide new insights into the 
connections between protein homeostasis and autoinflammation.  
https://clinicaltrials.gov/ct2/show/NCT01724580?term=NCT01724580&rank=1 [135] 

&$				&$
  
    The discovery of the physiologic role of pyrin by Feng Shao’s group represents a 
major advance in the field of autoinflammation [125,136]. The raison d’etre of the 
innate immune system is to protect the population from infection (Fig. 2); however, 
mutations in these protective genes can also lead to autoinflammatory disease.  
Shao and colleagues presented evidence that pyrin, as part of the pyrin 
inflammasome, acts as a sensor of different inactivating bacterial modification RHO 
GTPases, rather than directly interacting with these microbial products. This guard 
mechanism of pathogen detection has previously reported for pathogen recognition 
receptor (PRRs) in plants. Several Rho.inactivating bacterial toxins have been 
reported, including the TcdB toxin from Clostridium difficile the C3 toxin from 
Clostridium botulinum and the pertussis toxin from Bordetella pertussis, and, in the 
context of this review B. cenocepacia deamidates RhoA at Asn41 [125,136]. 
     More recent developments in this field include the discovery that RhoA activates 
the serine.threonine kinases PKN1 and PKN2 that bind and phosphorylate pyrin 
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[120]. This activation of PKN1 and PKN2 was found to decrease IL.1β release from 
peripheral blood mononuclear cells (PBMCs) of patients with FMF or HIDS. 
Defective prenylation, as seen in HIDS, was associated with RhoA inactivation and 
pyrin inflammasome activation (Fig. 4). Thus, the authors propose a novel molecular 
connection between FMF and HIDS. 
      Masters et al. have described an autoinflammatory disease, labelled pyrin.
associated autoinflammation with neutrophilic dermatosis (PAAND), caused by a 
mutation in pyrin, which disrupts pyrin regulation and mimics the effect(s) of 
pathogen sensing by pyrin, leading to proinflammatory IL.1β production [137]; the 
disease resolved in one patient by targeting IL.1β. These data reveal a regulatory 
mechanism of pyrin activation and suggest that it is regulated through a guard.like 
mechanism, which prevents the development and progression of autoinflammation. 
     A number of fundamental questions arise from these fascinating discoveries, 
including the precise molecular mechanisms of pyrin inflammasome activation and 
whether specific environmental factors may trigger attacks in patients with 
autoinflammation. 
 
 +


   Gain.of.function mutations in the NLRC4 gene a novel inflammasome disorder 
associated with predisposition to macrophage.activation syndrome (MAS) and highly 
elevated IL.18 levels [14] (Table 1). Aksentijevich and colleagues [138] found that 
TNFAIP3 mutations cause haploinsufficiency of A20 (HA20), with reduction of NF.κB 
[139] and IL.1 signalling leading to A20 haploinsufficiency, in an early.onset 
autoinflammatory disease, where the phenotype resembles Behcet’s disease [140]. 
A paper in press by the same group describes another NF.κB mediated disease, 
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caused by loss.of.function mutations in OTULIN/FAM105B gene, encoding a 
deubiquitinase with linear linkage specificity. These patients have a very severe 
phenotype, surprisingly resembling CANDLE, but clinically responsive to TNF 
inhibitors [141]. Together with HA20 these two diseases described a new category of 
autoinflammatory diseases, due to dysregulated ubiquitination. Thus the 
ubiquitination pathway has assumed greater important in the investigation of 
systemic autoinflammatory disorders of undefined etiology (SAIDs).  
Mutations in the TNFRSF11A gene have been reported in patients with a 
disease that has clinical similarities to TRAPS [142]. A report of a novel digenic 
pattern of inheritance in CANDLE/PRAAS patients, has provided insights into 
proteasome dysfunction and associated IFN production [66]. 
 
 
		
	

     Autoinflammatory diseases are mainly driven by proinflammatory cytokines, 
usually generated as a result of cellular stress, and especially oxidative stress with 
associated mitochondrial DNA (mtDNA) damage. The resulting release of metabolic 
mediators such as mitochondrial ROS, which acts as a DAMP for the NLRP3 
inflammasome activation [143]. The search for identifiable (exogenous) factors that 
might serve to trigger attacks of autoinflammation involves careful the patient’s 
environment, diet, or lifestyle [110]. Some known triggers known to influence the 
effects of individual mutations include  
1. Generalised exposure to cold may precipitate attacks of fever in familial cold 
autoinflammatory syndrome (FCAS). 
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2.  Attacks of HIDS may be triggered by trauma, illnesses or vaccine reactions 
[117,144]. A severe inflammation reaction following vaccination against 
Streptococcus pneumoniae has been described in patients with CAPS [142] 
3. Urate and CPP crystals cause NLRP3 inflammasome activation in gout and 
calcium pyrophosphate deposition disease (CPPD) [77] 
4. The pyrin inflammasome is activated upon bacterial toxin.induced modification of 
host Rho GTPases [125]. 
,Dying cells have the capacity to activate the innate immune system and induce a 
sterile inflammatory response [145,146]; necrotic cells are sensed by the Nlrp3 
inflammasome with subsequent release of IL.1β [147]. In a mouse model 
mitochondria were critical to activation of the Nlrp3 inflammasome by direct binding 
of Nlrp3 to the inner mitochondrial lipid cardiolipin. 
-The relationship between IFN.α and brain pathology in AGS is poorly understood 
[148]. Viral infection and replication introduces single.stranded RNA (ssRNA), 
double.stranded RNA (dsRNA) and DNA:RNA hybrids, with induction of type I IFN 
genes. The AGS phenotype may resemble congenital viral  and individual subsets of 
SLE [43,44].   
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     It is now accepted that innate immune.mediated inflammation plays a key role in 
the pathogenesis of some of the more common chronic systemic conditions, such as 
Crohn’s disease [4], type 2 diabetes (T2D) and a myeloid subset of rheumatoid 
arthritis (RA) [149], as well as in diseases not formerly considered inflammatory, 
such as neurodegenerative conditions [150]. There is increasing evidence that cell 
intrinsic or environmental alterations in protein homeostasis may contribute to the 
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pathogenesis in these conditions; thioredoxin.interacting P (TXNIP) serves as a 
functional link between ER stress, NLRP3 inflammasome activation and 
inflammation related to T2DM [151].  
 
&
 As the field of autoinflammatory disorders has developed so rapidly clinicians and 
researchers have produced guidelines to optimise and disseminate 
recommendations for universal management of children and young adults with these 
disorders. An international panel of 22 experts was established to develop evidence.
based recommendations for the management and treatment of CAPS, TRAPS and 
MKD using the European League Against Rheumatism (EULAR) standard operating 
procedures for developing best practice [152,153].           

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The continuously expanding number of monogenic diseases, for which 
susceptibility genes have been found, and which present with a range of overlapping 
clinical features, both autoinflammatory and autoimmune in nature, has raised the 
question as to how to (sub)classify those conditions, as the terms autoinflammation 
and/or autoimmunity are insufficient to adequately describe them. In addition to the 
challenge posed by these conditions with overlapping features, a range of other 
diseases, with variable clinical manifestations of immunodeficiency and immune 
dysregulation/autoimmunity have been genetically delineated. These include 
PLCG2.associated antibody deficiency and immune dysregulation (PLAID) [154], 
haploinsufficiency of CTLA.4, caused by heterozygous germline mutations [155] and 
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XLPDR disorder, due to deficiency of POLA1, which encodes the catalytic subunit of 
DNA polymerase.α [156]. This latter condition also has an associated IFN signature.  
Despite these observations, a combination of both pathogenic innate and 
adaptive immune responses underlie the immunopathology of most inflammatory 
conditions. As reviewed in [46] some clinical features, like B.cell immunodeficiency, 
may arise in conditions which are mainly innate.immune driven, and 
autoinflammatory in phenotype, such as deficiency of adenosine deaminase 2 
(DADA2) [157,158] but B.cell immunodeficiency may also be found in monogenic 
autoimmune conditions, like haploinsufficiency of CTLA.4 and PLAID. Furthermore, 
AGS7 has the potential to progress from being primarily innate.immune driven to 
becoming an antibody.mediated disease.  
          In light of the expanding number of overlapping syndromes of both 
autoinflammation and autoimmunity we propose to broaden the classification of 
diseases by assigning the term 	
	
	$. Conditions 
like PLAID, where the clinical picture combines features of immunodeficiency as well 
as autoimmunity, and, arguably, the cold urticaria element of PLAID is innate 
immune related, might also be considered; following the template proposed above 
complex conditions of that nature could be referred to as an 	
	

	$
	
$However the primary 
immunodeficiency diseases (PI) constitute an extensively classified group 
of conditions, and it may not be possible to find a satisfactory all.purpose blanket 
term for novel complex conditions with features of immunodeficiency as well as 
autoimmunity and autoinflammation. 


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The identification of a genetic aetiology for an increasing number of 
autoinflammatory diseases has led to a growing recognition that dysregulation of this 
normal defence mechanism may be more prevalent than previously realised in other 
diseases. Autoinflammation is likely to play a variable role in a wide spectrum of 
human disease, acting within a milieu of complex processes, involving innate and 
adaptive immunity. Understanding the role of autinflammation in various diseases 
processes is essential if new targets are to be identified for future therapies. 
 A major part of the human immune system’s basic function is to control the 
host’s relationship with his/her microbiota, referring to the the totality of 
microorganisms that inhabit the human body in health and disease. Recent major 
technological advances, including single cell sampling and shotgun sequencing 
enables detailed study of individual microbiota and inflammatory disease can related 
to components of the microbiome [159] (the combined genetic material of the 
microorganisms), and to the intracellular pathways that pathogens within the 
microbiome may dysregulate survive [160]. It is most likely that the widespread 
influence of intracellular microbes on innate immune defences and autoinflammatory 
diseases will be elaborated in significant detail in the next decade. 
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Diseases of the immune system are classified according to whether the lymphocyte 
responsible for the disease is of myeloid (autoinflammation) or lymphoid lineage 
(autoimmune). Clinical heterogeneity within immunological diseases may reflect the 
variable expression of autoinflammatory and autoimmune factors in disease 
causation.  
A disease spectrum that includes rare monogenic diseases at the polar ends of the 
spectrum, and polygenic diseases, involving both myeloid and lymphoid cells in 
pathogenesis, occupying the centre [10]. This diagram adds a third variable, 
environmental triggers, to further define the pathogenesis of these diseases. The 
figure does not include all immunologically recognised diseases because of their 
large number. 
HIDS. hyper IgD syndrome, CAPS. cryopyrin.associated autoinflammatory 
syndrome, FMF. familial Mediterranean fever, TRAPS. tumour necrosis factor 
receptor associated periodic syndrome, sJIA. systemic juvenile idiopathic arthritis, 
AOSD. adult onset Still’s disease, RA. rheumatoid arthritis, CF. cystic fibrosis, SLE. 
systemic lupus erythematosus, T1D. type 1 diabetes,  APS.1. autoimmune 
polyglandular syndrome type 1, PLAID. PLCG2 associated antibody deficiency and 
immune dysregulation, ALPS. autoimmune lymphoproliferative syndrome, IPEX. 
immune dysregulation polyendocrinopathy enteropathy X.linked syndrome.  
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Anactivating signal is required for the NLRP3 inflammasome to be assembled . 
examples include ATP.dependent K efflux, particulate substances, such as urate 
crystals entering the cell through lysosomal degredation pathways, mitochondrial 
damage and release of mtDNA or mtROS and intracellular pathogen recognition. 
The ligand for the NLRP3 inflammasome in humans is pro.caspase.1. Once 
activated, caspase.1 cleaves and activates inactive cytokines pro.IL.1β and pro.IL.
18. A second priming signal is required to induce pro.IL.1β and pro.IL.18 expression. 
This is typically through NF.κB signalling, downstream of TLRs, or through XBP.1 
downstream of the UPR. Once the inflammatory stimulus has subsided the NLRP3 
inflammasome is cleared by autophagolysosomal degradation. 
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CF shares many common features of autoinflammatory diseases. Due to the 
mutated CFTR, there is increased ROS signalling and reduced antioxidant secretion. 
CF also manifests with hyperuricaemia, low airway surface pH, ASL dehydration and 
high glucose levels, all thought to be triggers of the NLRP3 inflamamsome. CFTR 
mutations may cause extreme ionic imbalances, many of which have been linked 
with NLRP3 inflammasome activation. As the CFTR is misfolded in many genotypes 
of CF, this results in ER stress, UPR activation, and XBP1 signalling. Finally, 
increased lung infections provide frequent activation of the TLR.NF.κB inflammatory 
signalling pathway, priming the NLRP3 inflamamsome. 
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        When mutations in the NLRP3 inflammasome pathway or excessive/continuous 
stimuli interfere with its activation or priming, this inflammasome becomes the hub of 
life.limiting innate immune.driven diseases. Gout (yellow arrow), TRAPS (green 
arrow), MWS (red arrow), FMF (blue arrow) and HIDS (orange arrow) are examples 
of autoinflammatory conditions where the NLRP3 inflammasome is at the centre of 
disease pathology.    
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 An update on the mechanisms involved in the autoinflammatory diseases mentioned 
in this review. A more comprehensive list of these diseases exists in de Jesus et al.’s 
review [3].   
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